Angiotensin News and Research

RSS
Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.
FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

FDA approves Actavis' ANDA for Telmisartan Immediate-Release Tablets

FDA approves Actavis' ANDA for Telmisartan Immediate-Release Tablets

Patients with Loeys-Dietz syndrome at increased risk for aortic aneurysm

Patients with Loeys-Dietz syndrome at increased risk for aortic aneurysm

New guideline to help doctors treat patients with hypertension

New guideline to help doctors treat patients with hypertension

Studies highlight potential negative effects of soft drinks, sugar on kidney health

Studies highlight potential negative effects of soft drinks, sugar on kidney health

Oral allergy syndrome sufferers with hypertension may be at increased risk for severe reaction

Oral allergy syndrome sufferers with hypertension may be at increased risk for severe reaction

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

ASN strongly recommends all adults to undergo routine screening for chronic kidney disease

ASN strongly recommends all adults to undergo routine screening for chronic kidney disease

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Certain blood pressure medications may reduce risk of dementia due to Alzheimer's disease

Certain blood pressure medications may reduce risk of dementia due to Alzheimer's disease

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Insomnia poses hypertension risk

Insomnia poses hypertension risk

Simple method helps identify individuals who retain too much sodium

Simple method helps identify individuals who retain too much sodium

Aliskiren does not slow progression of coronary atherosclerosis in prehypertension patients

Aliskiren does not slow progression of coronary atherosclerosis in prehypertension patients

AQUARIUS trial data shows Aliskiren reduced incidents of death, stroke, heart attack

AQUARIUS trial data shows Aliskiren reduced incidents of death, stroke, heart attack

Renin inhibitor aliskiren not effective in slowing progression of coronary atherosclerosis

Renin inhibitor aliskiren not effective in slowing progression of coronary atherosclerosis

Hypertension researcher receives Distinguished Scientist title from AHA

Hypertension researcher receives Distinguished Scientist title from AHA

Implementation of large-scale hypertension program linked with doubling of hypertension control rates

Implementation of large-scale hypertension program linked with doubling of hypertension control rates

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.